NL-OMON28412招募中不适用
First in-human study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett¡¯s Esophagus
Academic Medical Center, Amsterdam (AMC)0 个研究点目标入组 9 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •a.Subject is between 22 ¨C 85 years of age.
排除标准
- •a.Subject has any condition that in the opinion of the PI preclude enrollment into the trial.
研究者
相似试验
已完成
2 期
First in-human study on the Safety, Tolerability and Efficacy of the Aqua Medical focal vapor ablation system, for the eradication of Barrett*s EsophagusEsophageal CarcinomaIntestinal Metaplasia1001799010017987NL-OMON49629Academisch Medisch Centrum15
已完成
1 期
First-in-human study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of NOX-H94MedDRA - LLT 10002272 (Anämie / Anemia)D63Anaemia in chronic diseases classified elsewhereDRKS00003102OXXON Pharma AG64
进行中（未招募）
1 期
A study in healthy male volunteers to look at the safety and tolerability of the new test medicine GUB014295 and how it is taken up by the body when given as a single dose by injectioControlling obesityNutritional, Metabolic, EndocrineISRCTN85112396Gubra A/S48
进行中（未招募）
1 期
First in human study to test the safety and preliminary efficacy of PPSGG, an antibody catcher in patients with anti-MAG neuropathyEUCTR2020-000067-23-FRPolyneuron Pharmaceuticals AG48
进行中（未招募）
1 期
First in human study to test the safety and preliminary efficacy of PPSGG, an antibody catcher in patients with anti-MAG neuropathyanti-MAG neuropathyMedDRA version: 21.1Level: LLTClassification code 10066137Term: Anti-MAG neuropathySystem Organ Class: 100000004852EUCTR2020-000067-23-GBPolyneuron Pharmaceuticals AG48